IP Library › Granted Patent US 10,323,100
Granted Patent B1
US 10,323,100 · App. 16/222,792 · Granted Jun 18, 2019

Hybridoma cell line of secreting clarithromycin monoclonal antibodies and preparation method thereof

Inventors: Chuanlai Xu (Jiangsu, CN); Hua Kuang (Jiangsu, CN); Lu Zeng (Jiangsu, CN); Liguang Xu (Jiangsu, CN); Liqiang Liu (Jiangsu, CN); Shanshan Song (Jiangsu, CN); Xiaoling Wu (Jiangsu, CN); Yongming Hu (Jiangsu, CN)
Assignee: JIANGNAN UNIVERSITY
C07K16/44A61K31/7048C07K16/065C12N5/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,323,100
App. No.
16/222,792
Granted
Jun 18, 2019
Kind
B1
Abstract

A hybridoma cell line of secreting clarithromycin monoclonal antibodies with a preservation number of hybridoma cell line of CGMCC No. 14696 belongs to the field of food safety immunological detection. BALB/c mice are immunized through one time immunization with complete freund's adjuvant, three times of booster immunization with incomplete freund's adjuvant and one time of rush immunization with clarithromycin complete antigen without adjuvant; the spleen cells from BALB/C mice immunized with high potency and low value of IC50 are fused with murine myeloma cells; and then the hybridoma cell line is obtained through indirect competitive ELISA screening and three subclones. The monoclonal antibody secreted by this cell line has good specificity and detection sensitivity to clarithromycin (value of IC50 is 0.3 ng/ml), being suitable for detection of clarithromycin in food.

Claims (2)

1. A hybridoma cell line of secreting clarithromycin monoclonal antibodies deposited with the general microbiological center of the China General Microbiological Culture Collection Center (No. 1 West Beichen Road, Chaoyang District, Beijing, China) under Accession Number CGMCC No. 14696 at Sep. 5, 2017.

2. A clarithromycin monoclonal antibody obtained from the hybrid tumor cell line of claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2018
From: XU, CHUANLAI; KUANG, HUA; ZENG, LU; XU, LIGUANG; LIU, LIQIANG; SONG, SHANSHAN; WU, XIAOLING; HU, YONGMING
To: JIANGNAN UNIVERSITY
Reel/Frame 047799/0799 →
Priority Claims (1)
CN 2018 1 0219848 · Mar 16, 2018 · national
Cited By (1)
US 12,583,942